# Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

> **NCT03390738** · PHASE2 · WITHDRAWN · sponsor: **The University of Hong Kong**

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03390738
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06
- **Primary completion:** 2019-05
- **Final completion:** 2019-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrew funding for Nivolumab
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03390738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03390738, "Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03390738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*